Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

1.02USD
4:00pm EDT
Change (% chg)

$-0.07 (-6.42%)
Prev Close
$1.09
Open
$1.05
Day's High
$1.05
Day's Low
$0.90
Volume
731,248
Avg. Vol
216,803
52-wk High
$9.95
52-wk Low
$0.65

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $15.42
Shares Outstanding(Mil.): 17.69
Dividend: --
Yield (%): --

Financials

  TROV.OQ Industry Sector
P/E (TTM): -- 38.68 32.14
EPS (TTM): -4.10 -- --
ROI: -130.20 13.89 12.83
ROE: -173.32 16.74 14.95

BRIEF-Trovagene Completes First Dosing Cohort Of Patients In Phase 1B/2 Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF FIRST DOSING COHORT OF PATIENTS IN ONGOING PHASE 1B/2 TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

May 17 2018

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

May 10 2018

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

May 08 2018

Earnings vs. Estimates